Relmada Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.282; its P/E ratio is -1.42; Relmada Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.85. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22
Income Statement	-
Total Revenue	-	$ 96.40K	-	$ 0.00	$ 0.00
Gross Profit	-	$ 276.40K	$ -29.58M	-	-
EBIT	$ -23.32M	$ 29.99M	$ -45.41M	$ -38.74M	$ -45.51M
EBITDA	$ -23.32M	$ 29.99M	$ -45.41M	$ -38.74M	$ -45.51M
Net Income Common Stockholders	$ -22.00M	$ 29.99M	$ -37.94M	$ -39.42M	$ -39.93M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 106.27M	$ 132.44M	$ 148.32M	$ 184.15M	$ 211.96M
Total Assets	$ 109.15M	$ 135.57M	$ 152.91M	$ 187.12M	$ 215.77M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -106.27M	$ -132.44M	$ -148.32M	$ -184.15M	$ -211.96M
Total Liabilities	$ 8.42M	$ 10.10M	$ 12.47M	$ 20.78M	$ 18.92M
Stockholders Equity	$ 100.73M	$ 125.47M	$ 140.44M	$ 166.34M	$ 196.85M
Cash Flow	-
Free Cash Flow	$ -11.63M	$ -16.51M	$ -35.88M	$ -26.86M	$ -21.63M
Operating Cash Flow	$ -11.63M	$ -16.51M	$ -35.88M	$ -26.86M	$ -21.63M
Investing Cash Flow	$ 3.86M	$ 40.00M	$ -1.66M	$ 31.56M	$ -140.52K
Financing Cash Flow	-	-	$ 409.88K	$ 569.09K	$ 14.09M

Currency in USD

Relmada Therapeutics Earnings and Revenue History

Income Statement >

Relmada Therapeutics Debt to Assets

Balance Sheet >

Relmada Therapeutics Cash Flow

Cash Flow >

Relmada Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing